Latest news

• Lundbeck’s key products shine in Q2 but problems remain

  Sales of antidepressant Cipralex (escitalopram) and anti-epileptic Sabril (vigabatrin) also suffered  double-digit declines, more than offsetting growth of Lundbeck’s four strategic brands.

• Lundbeck and Otsuka start phase III for Rexulti in bipolar

  protection for Abilify and former blockbuster antidepressant Lexapro/Celexa (escitalopram).

• Surging sales of Lundbeck's CNS drugs assist recovery

  Since its former blockbuster Cipralex (escitalopram) started to succumb to generic competition, Lundbeck has looked to two newer antidepressants - Brintellix/Trintellix (vortioxetine) and Rexulti (brexpiprazole) - to step in and fill the

• Lundbeck to cut 1,000 jobs in major restructure

  sales from drugs such as depression treatment Cipralex (escitalopram).

• US filing aims to elevate Brintellix above its competition

  Brintellix has been on the market in the US since 2013 and has been positioned as a successor to its older antidepressant Cipralex (escitalopram), which was selling around $2bn a year